Our vision is to create a pipeline of innovative biomedical assets in various stages of development in multiple therapeutic areas. Our strategy will minimize risk, share success and accelerate our technologies from incubation to monetization.
We are dedicated to acquiring and providing strategic resources and expansion capital to innovative healthcare companies that strive to provide much needed healthcare and related products to patients in need. By partnering with exceptional entrepreneurs we aim to help to create market-leading products in the biomedical and healthcare sector. As entrepreneurs and investors with operational and technical expertise we embrace a collaborative approach to capital formation and business development.
Preliminary scientific and commercial criteria review. Determining management’s expectations and flexibility moves the asset to the next step.
Due diligence is combined with a validation of management’s
development and capital requirements.
Performance-based capital is deployed to meet specific and mutually agreed goals in each stage
Additional resources are infused to move the asset through development stages and to a value-creating inflection point.
Assets can be sold, licensed, joint-ventured or operated as cash flow positive product lines. QBIO’s goal is to maximize value for its shareholders.
THE RIGHT FIRM
Focuses exclusively in the biotechnology and healthcare sectors, targeting a broad spectrum of biomedical products and healthcare solutions. Q’s expertise is in business & product development and the capital formation required for phased advancement of products.
THE RIGHT SOLUTION
Our team assists companies by utilizing our strategic partners and network of experts to provide public market access for private company assets. 80% of biomedical start ups lack capital and resources to transition from incubation to development and beyond.
THE RIGHT STRATEGY
Q expects to maximize risk-adjusted returns by focusing on value-driven assets from early stage to near-revenue businesses where the technical, regulatory, and commercial risks have been mitigated or where major valuation inflections are imminent.
Strontium Chloride Sr89 Injection, USP
Following intravenous injection, soluble strontium compounds behave like their calcium analogs, clearing rapidly from the blood and selectively localizing in bone mineral. Uptake of strontium by bone occurs preferentially in sites of active osteogenesis, thus primary bone tumors and areas of metastatic involvement (blastic lesions) can accumulate significantly greater concentrations of strontium than surrounding normal bone. Strontium-89 Chloride is retained in metastatic bone lesions much longer than in normal bone, where turnover is about 14 days. In patients with extensive skeletal metastases, well over half of the injected dose is retained in the bones. Excretion pathways are two-thirds urinary and one-third fecal in patients with bone metastases. Urinary excretion is higher in people without bone lesions. Urinary excretion is greatest in the first two days following injection. Strontium-89 is a pure beta emitter and Strontium-89 Chloride selectively irradiates sites of primary and metastatic bone involvement with minimal irradiation of soft tissues distant from the bone lesions. (The maximum range in tissue is 8 mm; maximum energy is 1.463 MeV.) Clinical trials have examined relief of pain in cancer patients who have received therapy for bone metastases (external radiation to indexed sites) but in whom persistent pain recurred.
About QBM – 001
QBM-001 is given to high-risk genetically identified children during the second year of life to regulate faulty membrane channels that are known to cause migraines and/or seizures. This drug acts as an allosteric regulator of these faulty channels in the brain to potentially alleviate the condition and allow toddlers to actively develop language and speech and avoid life-long speech and intellectual disability of being non-verbal. QBM-001 also reduces inflammation in the brain and by so doing can reduce the amount of long-term nerve loss.
About UTTROSIDE-B Chemotherapeutic
P Uttroside-B appears to affect phosphorylated JNK (pro survival signaling) and capcase activity (apoptosis inliver cancer)
> A natural compound
> Fractionated Saponin derived from S. nigrum
> Small molecule
> Steroid Glycoside
Uttroside B increases the cytotoxicity of a variety of liver cancer cell types
> Up to 10x more potent than Sorafenib in pre clinical studies
Topical Eyedrops for Glaucoma
First in class drug for Intraocular Eye Pressure. No new drugs in”IOP” for 20 years Only drug targeting the critical ‘Schlemms’ Canal. The Schlemms Canal is responsible for 70%-90% of fluid drainage in the eye.
We are developing a unique set of molecules to treat vascular related diseases, such as Primary Open Angle Glaucoma, Pediatric Glaucoma, Cystic Kidney Disease, and Inflammation via our proprietary research platform.
MAN-01 faciltiates the drainage of liquid through the Schlemm’s Canal testing on mice as consistently delivered positive results in relieving IOP.
Denis D Corin
CEO and Chairman
Mr. Denis D. Corin is Chief Executive Officer and Chairman of the Board. Mr. Corin is an experienced public company executive and management consultant. He has worked almost exclusively in the biomedical field for over 13 years from large pharma and diagnostic companies to small innovative biotech. He has served in various senior executive roles and has been instrumental in building and restructuring businesses. Mr. Corin has raised millions of dollars in development capital to advance businesses. Mr. Corin also served as a Management Consultant to the executives and board of TapImmune Inc. (NASD:TPIV), a clinical stage immune-oncology company through 2014, He holds a Bachelors Degree majoring in both Economics and Marketing & Advertising Management from the University of Natal, South Africa.
General Counsel and Director
Mr. William Rosenstadt is a partner and a co-founder of Ortoli Rosenstadt LLP and head of the firm’s capital markets and securities practice and co-chair of the firm’s Asian practice. He has been practicing corporate and securities law since 1995. He represents entrepreneurs, public companies, hedge funds, private equity funds and other corporate entities on complex international and corporate transactions. He has represented public companies in the U.S., Europe and Asia. William is proud to be given the opportunity to help Q BioMed create value for its shareholders and bring life changing solutions to as many patients as possible.
VP Product Development
Mr. Laskow-Pooley has 30 years of experience in all aspects of the discovery, development and commercialization of pharmaceutical products, diagnostics and devices. He is an industry veteran and has a distinguished career working for numerous pharmaceutical and life sciences companies. He has held director, executive officer and general management posts in both small and major multinational companies including GSK, Abbott, Amersham plc, Life technologies, OSI, Bilcare and Surface Therapeutics.
Business Development Analyst
Mr. Ari Jatwes is an analyst and a banker, with over twenty years of experience. He began his career in a large accounting firm, progressing to a reputable investment bank, where he gained his experience in mergers and acquisitions. Over the last decade Mr. Jatwes interest and focus has been in the biotech and pharma sector, which included trading biotech stocks from start up to late stage biotech companies, advising management and raising capital for their needs. He has played a role in several successful contracts and transactions in the healthcare space – with emphasis on the life sciences and immunotherapy. Mr. Jatwes holds two Master degrees and a Bachelor Degree from the University of South Africa and the University of Natal.
VP Orphan Products
Robert Derham has focused the majority of his career working with rare diseases and orphan products. For the past seven years he has focused on driving corporate change within medium and large pharmaceutical companies to transition their corporate strategy to an orphan drug development approach. In addition to driving corporate change, he conducted business development for companies looking for partnering, licensing or acquisition opportunities in the orphan drug space. Prior to that, he worked for Mondobiotech, Novartis, Syngenta Biopharma and Alexis Biopharma, always focused on orphan indications and corporate development. Robert is also the founder of CheckOrphan, a comprehensive media and information source for all news, videos, clinical trials, research, treatments and more about rare diseases and orphan products. He also has degrees in medical immunology and biochemistry and thoroughly enjoys diving into the science and research of the rare diseases, with which he is working.
Dr. Rick Paniccucci
Director and Advisor Pharmaceutical Development
Dr. Rick Panicucci is the Vice President of Pharmaceutical Development at WuXi AppTec. He is responsible for providing scientific leadership in the areas of Developability, Formulation Development and GMP Manufacturing.Dr. Panicucci plays an important role in the early stages of drug discovery for various companies. His responsibilities include solid state chemistry and formulation development of all small molecule therapeutics in early development, and developing novel drug delivery technologies for small molecules and large molecules including siRNA.Prior to WuXi he held the position of Global Head of Chemical and Pharmaceutical Profiling (CPP) at Novartis from 2004 to 2015, where he led the development and implementation of innovative dosage form designs and continuous manufacturing paradigms. He has also held positions as the Director of Formulation Development at Vertex Pharmaceuticals and Senior Scientist at Biogen.Dr. Panicucci received his Ph.D. in Physical Organic Chemistry at the University of Toronto, and has two post doctoral fellowships at University of California at Santa Barbara and the Ontario Cancer Institute. Dr. Panicucci will advise our technology partner, Mannin Research Inc.’s development both scientifically and commercially.
Advisor Medicinal Chemistry
Dr. Amy Ripka is Executive Director of Medicinal Chemistry at WuXi AppTec. She started her career at Bristol Myers Squibb and over 17 years has worked in various capacities in medicinal chemistry with many small companies, including EnVivo (FORUM) Pharmaceuticals as Head of Chemistry, Infinity, Daiamed, HydraBiosciences and FoldRx. Her current responsibilities include strategic planning in medicinal chemistry, early library drug design utilizing multiple in silico methods, hit optimization and overall screening architectures to advance early stage compounds through Phase I-II clinical development. Dr. Ripka’s therapeutic specialties include Neuroscience, Oncology, Thrombosis and Anti-Infective Disease areas. She has led multiple early stage programs resulting in four clinical candidates, two of which are marketed drugs. Her career has spanned big pharma, biotech and CROs where she has made significant contributions to each of these.Dr. Ripka, was elected by her peers to Chair the prestigious Medicinal Chemistry Gordon Research Conference and is currently serving a second elected term as the Industrial Councilor for the MEDI Division of the American Chemical Society.Dr. Ripka, received her Ph.D. in Chemistry from the University of Wisconsin-Madison with a double concentration in organic and medicinal chemistry, and did her post-doctoral studies with Nobel Laureate K. Barry Sharpless from The Scripps Research Institute. Dr. Ripka will advise Mannin’s scientific development and growth.
FN Media Group LLC (FNMG) owns and operates FinancialNewsMedia.com (FNM) which is a third party publisher that disseminates electronic information through multiple online media channels. FNMG’s intended purposes are to deliver market updates and news alerts issued from private and publicly trading companies as well as providing coverage and increased awareness for companies that issue press to the public via online newswires. FNMG and its affiliated companies are a news dissemination and financial marketing solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNMG’s market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. The companies that are discussed in this release may or may not have approved the statements made in this release. Information in this release is derived from a variety of sources that may or may not include the referenced company’s publicly disseminated information. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. While this information is believed to be reliable, such reliability cannot be guaranteed. FNMG disclaims any and all liability as to the completeness or accuracy of the information contained and any omissions of material fact in this release. This release may contain technical inaccuracies or typographical errors. It is strongly recommended that any purchase or sale decision be discussed with a financial adviser, or a broker-dealer, or a member of any financial regulatory bodies. Investment in the securities of the companies discussed in this release is highly speculative and carries a high degree of risk. FNMG is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. This release is not without bias, and is considered a conflict of interest if compensation has been received by FNMG for its dissemination. To comply with Section 17(b) of the Securities Act of 1933, FNMG shall always disclose any compensation it has received, or expects to receive in the future, for the dissemination of the information found herein on behalf of one or more of the companies mentioned in this release. For current services performed FNMG has been compensated forty six hundred dollars for Q BioMed Inc. current news coverage by the company. FNMG HOLDS NO SHARES OF Q BioMed Inc.
This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNMG undertakes no obligation to update such statements.